Echinocandins B 市场 - 全球产业规模、份额、趋势、机会、预测：按类型、应用、地区和竞争格局划分，2021-2031 年

全球EchinocandinsB市场预计将从2025年的475.8亿美元成长到2031年的657.5亿美元，复合年增长率达到5.54%。

EchinocandinsB是一种关键的脂肽中间体，通常透过曲菌属真菌发酵获得，是合成Echinocandins类抗真菌药物（如阿尼芬净）的必需原料。此市场成长的主要驱动力是全球侵袭性真菌感染疾病发生率的上升，以及免疫力缺乏患者对Azole抗药性病原体有效治疗的需求。日益加重的疾病负担也支持了这项需求。根据全球预防真菌感染疾病基金（GAFF）2024年的预测，全球每年约有655万人受到危及生命的真菌疾病的影响，这直接催生了对这些重要药物前体的需求。

儘管市场需求强劲，但由于Echinocandins类药物的治疗成本高于传统的Azole药物，因此面临巨大的市场障碍。EchinocandinsB核的生产需要复杂的发酵和半合成工艺，这导致生产成本增加，最终必然反映在最终价格上。这种经济障碍阻碍了这些疗法在医疗预算有限且对价格敏感的发展中地区的广泛应用，从而限制了市场扩张的整体潜力。

市场驱动因素

多重抗药性真菌病原体的日益增加是推动全球EchinocandinsB市场扩张的主要因素。随着器官移植和肿瘤治疗的增加，免疫力缺乏患者的数量不断增长，导致他们更容易感染严重的真菌，因此需要建立健全的棘Echinocandins中间体供应链。耳Auris等病原体的快速传播凸显了这种紧迫性，这些病原体通常对传统的Azole药物具有抗药性，使得Echinocandins类药物成为首选的第一线治疗方案。根据美国疾病管制与预防中心（CDC）于2024年12月发布的《追踪耳念珠菌》监测报告，2023年美国该多重抗药性真菌的临床病例数达到4514例，显示这一趋势仍在持续，直接推高了对高效脂肽类抗真菌药物的需求。

同时，新型抗真菌药物製剂的研发扩张推动了对高纯度EchinocandinsB核的需求，并重塑了市场动态。製药公司正积极推动下一代Echinocandins的商业化，这些药物具有更高的稳定性和更灵活的给药方案，而这一过程高度依赖先进的半合成生产技术。 2024年5月，Sidala Therapeutics在其2024年第一季财报中宣布，其新型Echinocandins药物rezafungin已接受欧盟核准，并从Mundipharma公司获得约1110万美元的里程碑付款，证实了这些先进治疗方法的商业性可行性。为了进一步体现对此治疗领域的信心，F2G在2024年获得了由AMR行动基金主导的1亿美元资金筹措，用于推进后期抗真菌药物的研发。这凸显了全球投资涌入该领域的重要性。

市场挑战

Echinocandins类药物的高昂价格严重阻碍了其市场扩张，尤其是在对成本高度敏感的发展中地区。EchinocandinsB核的生产涉及复杂的发酵和半合成工艺，这本身就增加了生产成本。这些高成本最终会转嫁到药品价格上，这对预算有限的医疗系统造成了巨大的经济负担。因此，儘管Echinocandins药物具有显着的临床疗效，但这些地区的医疗服务提供者不得不依赖传统的低成本Azole药物，这限制了这些先进疗法的潜在市场。

真菌感染疾病对医疗基础设施带来的广泛经济负担进一步加剧了价格敏感性，迫使管理者严格控制药品成本。根据美国感染疾病学会估计，到2024年，真菌感染疾病对美国造成的年度经济负担总额约为194亿美元。如此巨大的经济压力迫使医疗机构优先考虑成本控制，导致他们倾向于选择更经济实惠的替代疗法，进一步抑制了高端Echinocandins类药物的使用率，直接阻碍了全球EchinocandinsB市场规模的成长。

市场趋势

新一代长效衍生物的出现从根本上改变了Echinocandins中间体的商业性格局，将市场从每日给药方案（如阿尼芬净）转向每週一次的给药方案。这种转变要求EchinocandinsB核作为更高级化学修饰的基础，增加了技术复杂性和价值链价值。製药公司越来越倾向于将这些资本密集的研发项目出售给拥有专业商业基础设施的合作伙伴公司，以最大限度地提高市场渗透率。例如，Sidala Therapeutics在2024年8月发布的2024年第二季财报中宣布，预计在雷射芬净的专利权持续时间内可节省约1.28亿美元的成本。这是由于该公司将该资产策略性地出售给了Mundipharma进行全球商业化，并清楚地表明了整个行业将资源重新分配到高附加价值新一代疗法的趋势。

同时，关键专利的到期以及随后大型无菌注射剂生产商的涌入，正推动阿尼芬净原料药非专利药生产的快速扩张。这一趋势使Echinocandins菌素类疗法的可及性更加普及，迫使现有原料药生产商优化发酵产量，以在满足非专利核准所需的严格纯度标准的同时，保持价格竞争力。该领域的快速成长有利于那些拥有垂直整合能力、能够在价格压力下维持利润率的生产商。 2024年5月，Grand Pharma在「2024年第四季及全年财务业绩报告」中宣布，其合併销售额年增56%。这一成长主要得益于其核心无菌注射剂市场的强劲销售成长，反映了全球对高性价比非专利抗真菌製剂日益增长的需求。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：EchinocandinsB的全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（粉末、液体）
  • 依应用领域（抗真菌药物、药物研发等）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：EchinocandinsB北美市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：EchinocandinsB的欧洲市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区棘EchinocandinsB市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：EchinocandinsB在中东和非洲的市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：EchinocandinsB在南美的市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球EchinocandinsB市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Glenmark Pharmaceuticals Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Mylan NV
• Fresenius SE & Co. KGaA
• Merck & Co., Inc.
• Astellas Pharma Inc.
• Pfizer Inc.
• Cidara Therapeutics, Inc.
• Hikma Pharmaceuticals PLC

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Echinocandin B Market is projected to expand from USD 47.58 Billion in 2025 to USD 65.75 Billion by 2031, achieving a compound annual growth rate of 5.54%. Serving as a critical lipopeptide intermediate typically obtained through the fermentation of Aspergillus species, Echinocandin B is essential for synthesizing the echinocandin class of antifungal agents, such as anidulafungin. The market is driven primarily by the rising global incidence of invasive fungal infections and the urgent need for effective treatments against azole-resistant pathogens in immunocompromised patients. This demand is supported by the growing disease burden; the Global Action Fund for Fungal Infections estimated in 2024 that approximately 6.55 million people worldwide are affected annually by life-threatening fungal diseases, creating a direct requirement for these essential drug precursors.

Despite strong demand, the market encounters a significant obstacle due to the high cost of therapy associated with echinocandin-based drugs relative to conventional azoles. The intricate fermentation and semi-synthetic manufacturing processes needed to produce the Echinocandin B nucleus lead to elevated production costs, which are inevitably reflected in the final pricing. This financial barrier hinders the widespread adoption of these therapeutics in price-sensitive developing regions with limited healthcare budgets, thereby constraining the overall potential for market expansion.

Market Driver

The increasing prevalence of multidrug-resistant fungal pathogens is the primary force accelerating the Global Echinocandin B Market. As immunocompromised patient populations grow due to rising rates of organ transplants and oncological therapies, susceptibility to severe mycoses has intensified, necessitating robust supply chains for echinocandin intermediates. This urgency is highlighted by the rapid spread of pathogens such as Candida auris, which often displays resistance to traditional azole therapies, thus prioritizing echinocandin-class drugs as a first-line defense. According to the December 2024 'Tracking C. auris' surveillance report by the Centers for Disease Control and Prevention, clinical cases of this multidrug-resistant fungus in the U.S. reached 4,514 in 2023, indicating a continued upward trend that directly increases manufacturing requirements for effective lipopeptide-based antifungals.

Simultaneously, the expansion of pharmaceutical R&D for new antifungal formulations is reshaping market dynamics by driving demand for high-purity Echinocandin B nuclei. Pharmaceutical developers are actively commercializing next-generation echinocandins with enhanced stability and dosing schedules, a process heavily reliant on advanced semi-synthetic manufacturing. In May 2024, Cidara Therapeutics reported in its 'First Quarter 2024 Financial Results' that it received a milestone payment of approximately $11.1 million from Mundipharma following the European Union approval of the novel echinocandin rezafungin, confirming the commercial viability of these advanced therapies. Further reflecting confidence in this therapeutic area, F2G secured a $100 million financing round in 2024 led by the AMR Action Fund to advance late-stage antifungal development, underscoring the significant global investment entering the sector.

Market Challenge

The high cost of therapy associated with echinocandin-based drugs presents a significant hurdle to market expansion, particularly in cost-sensitive developing regions. Producing the Echinocandin B nucleus involves complex fermentation and semi-synthetic processes that inherently increase manufacturing expenses. These elevated costs are transferred to the final pricing, establishing a substantial financial barrier for healthcare systems with restricted budgets. Consequently, medical providers in these areas often resort to conventional, lower-cost azoles despite the clinical benefits of echinocandins, thereby limiting the addressable market for these advanced therapeutics.

This price sensitivity is further exacerbated by the broader economic strain that fungal diseases place on healthcare infrastructure, forcing administrators to strictly manage pharmacy expenditures. According to the Infectious Diseases Society of America, the total annual economic burden of fungal diseases in the United States was estimated to be approximately $19.4 billion in 2024. Such immense financial pressure compels healthcare institutions to prioritize cost containment, further suppressing the adoption rates of premium echinocandin treatments in favor of more affordable alternatives, which directly hampers volume growth in the Global Echinocandin B Market.

Market Trends

The rise of next-generation long-acting derivatives is fundamentally altering the commercial landscape for echinocandin intermediates, shifting the market from daily formulations like anidulafungin toward weekly dosing regimens. This transition requires the Echinocandin B nucleus to serve as a scaffold for more advanced chemical modifications, thereby increasing the technical complexity and value of the supply chain. Pharmaceutical companies are increasingly divesting these capital-intensive development programs to partners with specialized commercial infrastructure to maximize market penetration. For instance, Cidara Therapeutics projected in its 'Second Quarter 2024 Financial Results' in August 2024 that it would achieve approximately $128 million in cost savings over the patent life of rezafungin following the strategic divestiture of the asset to Mundipharma for global commercialization, illustrating the industry-wide push to realign resources toward these high-value, next-generation therapies.

At the same time, the market is experiencing a rapid expansion of generic anidulafungin API production, driven by the expiration of key patents and the subsequent entry of large-scale sterile injectable manufacturers. This trend is democratizing access to echinocandin therapies, forcing incumbent API producers to optimize fermentation yields to compete on price while meeting the stringent purity standards required for generic regulatory approvals. The intense volume growth in this segment benefits manufacturers with vertically integrated capabilities who can sustain margins despite pricing pressures. In May 2024, Gland Pharma reported a 56% year-over-year increase in consolidated revenue in its 'Financial Results for the Fourth Quarter and Full Year ended March 31, 2024', a surge attributed to robust volume growth in its core sterile injectable markets, validating the accelerating global demand for cost-effective generic antifungal formulations.

Key Market Players

• Glenmark Pharmaceuticals Ltd.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Mylan N.V.
• Fresenius SE & Co. KGaA
• Merck & Co., Inc.
• Astellas Pharma Inc.
• Pfizer Inc.
• Cidara Therapeutics, Inc.
• Hikma Pharmaceuticals PLC

Report Scope

In this report, the Global Echinocandin B Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Echinocandin B Market, By Type

• Powder
• Liquid

Echinocandin B Market, By Application

• Antifungal Drugs
• Drug Development
• Others

Echinocandin B Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Echinocandin B Market.

Available Customizations:

Global Echinocandin B Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Echinocandin B Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Powder, Liquid)
  • 5.2.2. By Application (Antifungal Drugs, Drug Development, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Echinocandin B Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Echinocandin B Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Echinocandin B Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Echinocandin B Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application

7. Europe Echinocandin B Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Echinocandin B Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
  • 7.3.2. France Echinocandin B Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Echinocandin B Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Echinocandin B Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Echinocandin B Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application

8. Asia Pacific Echinocandin B Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Echinocandin B Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
  • 8.3.2. India Echinocandin B Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Echinocandin B Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Echinocandin B Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Echinocandin B Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Application

9. Middle East & Africa Echinocandin B Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Echinocandin B Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Echinocandin B Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Echinocandin B Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application

10. South America Echinocandin B Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Echinocandin B Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Echinocandin B Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Echinocandin B Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Echinocandin B Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Glenmark Pharmaceuticals Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Teva Pharmaceutical Industries Ltd.
• 15.3. Sun Pharmaceutical Industries Ltd.
• 15.4. Mylan N.V.
• 15.5. Fresenius SE & Co. KGaA
• 15.6. Merck & Co., Inc.
• 15.7. Astellas Pharma Inc.
• 15.8. Pfizer Inc.
• 15.9. Cidara Therapeutics, Inc.
• 15.10. Hikma Pharmaceuticals PLC

16. Strategic Recommendations

17. About Us & Disclaimer